From Our Perspective: FDA’s Actions Create Transparency and Value for Complex Generic Product Development - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. Generic Drugs in the 21st Century: FDA's Actions Create Transparency and Value for Complex Generic Product Development Advancing complex generic drug development is an important part of FDA's goal to help make sure patients have access to a broad range of potentially cost-saving medicines. Complex generic products generally have complex active ingredients, dosage forms, routes of administration, or drug-device combinations. Examples of complex products include inhalers, topical products, and extended release injectables. Generics of complex brand name drugs or reference listed drugs can be more difficult to develop. As such, a complex drug product is less likely to have an available generic. In this From Our Perspective, FDA's Robert Lionberger, PhD, Director of the Office of Research and Standards in CDER's Office of Generic Drugs, discusses the agency's actions to create transparency and value for complex generic product development. Read More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA